Ipsen adds cowork­ing to new Boston HQ with Bi­o­Labs part­ner­ship; NYC gets biotech start­up ac­cel­er­a­tor, fund­ed with $25M from state

→ French phar­ma Ipsen is go­ing to be play­ing host to a cowork­ing fa­cil­i­ty in Boston. Just weeks af­ter an­nounc­ing it was mov­ing its US head­quar­ters from New Jer­sey to Boston, Ipsen an­nounced Thurs­day that its shiny new HQ will have shared “in­no­va­tion” space. The phar­ma is team­ing up with Bi­o­Labs, a net­work of biotech cowork­ing spaces that has lo­ca­tions all over the coun­try.

The shared lab­o­ra­to­ry space, called the Ipsen In­no­va­tion Cen­ter – Bi­o­Labs, will span 15,000 square-feet. It will in­clude of­fice and lab­o­ra­to­ry space to sup­port en­tre­pre­neurs and star­tups. Ipsen is pro­vid­ing the space and some ed­u­ca­tion­al pro­grams, men­tor­ing and of­fice hours with Ipsen R&D teams, while Bi­o­Labs is man­ag­ing the op­er­a­tions. The space will open the first quar­ter of 2019, with Bi­o­Labs ac­cept­ing ap­pli­ca­tions for oc­cu­pan­cy in the com­ing months.

“Ex­ter­nal in­no­va­tion is core to Ipsen’s growth strat­e­gy and we are com­mit­ted to sup­port­ing the biotech ecosys­tem that plays such a vi­tal role in dis­cov­er­ing in­no­v­a­tive new ther­a­pies,” said Ivana Magov­če­vić-Liebisch, EVP and chief busi­ness of­fi­cer at Ipsen, in a state­ment. “Ipsen is ex­cit­ed to part­ner with Bi­o­Labs to es­tab­lish a world-class co-work­ing space that will pro­vide a launch­pad for the next gen­er­a­tion of high-im­pact biotechs.”

→ In the lat­est NYC tac­tic to spur its biotech scene, the state has hand­ed $25 mil­lion in fund­ing to busi­ness ac­cel­er­a­tor In­dieBio. The San Fran­cis­co-based group will be open­ing a space in New York City next year with the funds. In­dieBio is look­ing to work with 20 star­tups a year and says it will pro­vide each with up to $2 mil­lion in in­vest­ment dol­lars (along with the usu­al ac­cel­er­a­tor men­tor­ship). They’re look­ing for a 12,000 to 20,000 square-foot place, prefer­ably in Man­hat­tan near a ma­jor trans­porta­tion hub. “There is a huge amount of tal­ent that is un­tapped po­ten­tial in New York,” founder Arvind Gup­ta told the Wall Street Jour­nal. “Re­al­ly the chal­lenge will be gal­va­niz­ing that ecosys­tem and hav­ing it be­lieve there is a new way of start­ing bio-tech com­pa­nies that can be low­er cost, faster to mar­ket.” The state’s $25 mil­lion in­vest­ment will come over five years and is part of a $620 mil­lion ini­tia­tive to strength­en its life sci­ences re­search clus­ter.

→ The UK’s Do­mainex has opened up BD of­fices in Boston and San Diego.

M&A: a crit­i­cal dri­ver for sus­tain­able top-line growth in health­care

2021 saw a record $600B in healthcare M&A activity. In 2022, there is an anticipated slowdown in activity, however, M&A prospects remain strong in the medium to long-term. What are future growth drivers for the healthcare sector? Where might we see innovations that drive M&A? RBC’s Andrew Callaway, Global Head, Healthcare Investment Banking discusses with Vito Sperduto, Global Co-Head, M&A.

Abortion-rights protesters regroup and protest following Supreme Court's decision to overturn Roe v. Wade. (AP Photo/Gemunu Amarasinghe)

Fol­low­ing SCO­TUS de­ci­sion to over­turn abor­tion pro­tec­tions, AG Gar­land says states can't ban the abor­tion pill

Following the Supreme Court’s historic decision on Friday to overturn Americans’ constitutional right to an abortion after almost 50 years, Attorney General Merrick Garland sought to somewhat reassure women that states will not be able to ban the prescription drug sometimes used for abortions.

Following the decision, the New England Journal of Medicine also published an editorial strongly condemning the reversal, saying it “serves American families poorly, putting their health, safety, finances, and futures at risk.”

AstraZeneca's new Evusheld direct to consumer campaign aims to reach more immunocompromised patients.

As­traZeneca de­buts first con­sumer cam­paign for its Covid-19 pro­phy­lac­tic Evusheld — and a first for EUA drugs

AstraZeneca’s first consumer ad for Evusheld is also a first for drugs that have been granted emergency use authorizations during the pandemic.

The first DTC ad for a medicine under emergency approval, the Evusheld campaign launching this week aims to raise awareness among immunocompromised patients — and spur more use.

Evusheld nabbed emergency authorization in December, however, despite millions of immunocompromised people looking for a solution and now more widespread availability of the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

De­spite a slow start to the year for deals, PwC pre­dicts a flur­ry of ac­tiv­i­ty com­ing up

Despite whispers of a busy year for M&A, deal activity in the pharma space is actually down 30% on a semi-annualized basis, according to PwC’s latest report on deal activity. But don’t rule out larger deals in the second half of the year, the consultants said.

PwC pharmaceutical and life sciences consulting solutions leader Glenn Hunzinger expects to see Big Pharma companies picking up earlier stage companies to try and fill pipeline gaps ahead of a slew of big patent cliffs. Though a bear market continues to maul the biotech sector, Hunzinger said recent deals indicate that pharma companies are still paying above current trading prices.

Joe Wiley, Amryt Pharma CEO

Am­ryt Phar­ma sub­mits a for­mal dis­pute res­o­lu­tion to the FDA over re­ject­ed skin dis­ease drug

The story of Amryt Pharma’s candidate for the genetic skin condition epidermolysis bullosa, or EB, will soon enter another chapter.

After the Irish drugmaker’s candidate, dubbed Oleogel-S10 and marketed as Filsuvez, was handed a CRL earlier this year, the company announced in a press release that it plans to submit a formal dispute resolution request for the company’s NDA for Oleogel-S10.

Sen. Thom Tillis (R-NC) (J. Scott Applewhite/AP Images)

Phar­ma-friend­ly sen­a­tor calls on FDA for a third time to show patent pro­tec­tions should­n't be blamed for high drug prices

North Carolina Republican Sen. Thom Tillis made a name for himself in the 2020 election cycle as the darling of the pharma industry, accepting hundreds of thousands in campaign contributions, even from the likes of Pfizer CEO Albert Bourla.

Those contributions have led Tillis to attempt to re-write patent laws in pharma’s favor, a move which failed to gain steam in 2019, and request for a third time since January that the FDA should help stop “the false narrative that patent protections are to blame for high drug prices.”

EMA signs off on 3 drugs re­cent­ly re­ject­ed by FDA, in­clud­ing Bio­Mar­in's new he­mo­phil­ia gene ther­a­py

The EMA’s human medicines committee on Friday recommended three new drugs for approval or conditional approval, even as their US counterparts have rejected these three for various reasons.

In a major move, CHMP offered a thumbs-up to a conditional marketing authorization for the first gene therapy to treat severe hemophilia A, although the agency cautioned that it’s so far unknown how long the effects of infusion will last.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Joe Papa (Ryan Remiorz/The Canadian Press via AP, File)

Joe Pa­pa re­signs as chair of Bausch Health as bil­lion­aire John Paul­son takes over

Joe Papa, chair of Bausch Health, officially resigned on Thursday and the board appointed billionaire hedge fund manager John Paulson as the new chair, effective immediately.

The specialty pharma company sought to make clear that Papa’s abrupt departure “was not due to any dispute or disagreement with the Company, its management or the Board on any matter relating to the Company’s operations, policies or practices.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Yong Dai, Frontera Therapeutics CEO

Scoop: Lit­tle-known Or­biMed-backed biotech clos­es $160M round to start gene ther­a­py tri­al

Frontera Therapeutics, a China and US biotech, has closed a $160 million Series B and received regulatory clearance to test its first gene therapy stateside, Endpoints News has learned.

Led by the largest shareholder, OrbiMed, the biotech has secured $195 million total since its September 2019 founding, according to an email reviewed by Endpoints. The lead AAV gene therapy program is for an undisclosed rare eye disease, according to the source.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.